EPA / DHA-enriched enteral formulas account for 50.2% of product type revenue in 2026, with ARDS & respiratory failure at 40.8% and enteral feeds at 53.9%. Protocol-fit dosing supports hospital use, but uneven outcome evidence limits routine high-dose omega-3 feeding.
Critical Care Omega 3 Nutrition Market Analysis By End UserCritical Care Omega 3 Nutrition Market Analysis By IndicationCritical Care Omega 3 Nutrition Market Analysis By Product TypeCritical Care Omega 3 Nutrition Market Analysis By Sales ChannelCritical Care Omega 3 Nutrition Market Breakdown By Product Type, Indication, And RegionCritical Care Omega 3 Nutrition Market Opportunity Matrix Growth Vs Value